AbbVie's Allergan division has launched Boey, a botulinum toxin formulation designed for rapid onset, and has secured EU regulatory approval. The product targets the competitive gap where practitioners and patients seek faster results—traditionally a weakness of toxin injectables, which typically require 3–7 days for full effect.